Cardinal Health Inc
CAH: XNYS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|L! | LOCK|>x$< | LOCK|v$%<Cb |
New Customers, Solid Prescription Trend, and Growing Specialties Support Cardinal's Long-Term Growth
Business Strategy and Outlook
Cardinal Health is one of three leading domestic wholesalers of branded, generic, and specialty pharmaceutical products. With over $200 billion in annual US drug distribution sales in fiscal 2025, the firm supplies roughly one fourth of the overall market. Its two close competitors are Cencora and McKesson, and together, the three operate as a pharmaceutical wholesale and distribution oligopoly, supplying over 90% of the US market.
